Publications

Publications

Next-generation Sequencing of Urologic Cancers: Next Is Now

By:
Contributors: Paul Boutros, PhD
Eur Urol. 2014 Jul;66(1):4-7. doi: 10.1016/j.eururo.2014.03.028. Epub 2014 Apr 5

Abstract

The exomes/genomes of a few hundred kidney, bladder, and prostate tumours have been sequenced. This sequencing has unveiled new genes that are altered and new opportunities for tumour subclassification, prediction of outcome, and therapy. These opportunities will soon become realities.

 PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Nanostics is pleased to announce the launch of clinical validation study

EDMONTON, June 4, 2019 /CNW/ – Nanostics Inc. is pleased to Announce the start of its key Clinical validation study. APCaRI is managing the study and recruitment has begun at Calgary’s Prostate Cancer Centre (PCC) and Edmonton’s Northern Alberta Urology Centre (NAUC). Recruitment of men from the Yukon Territories will follow.
The study will be conducted in partnership with DynaLIFE Medical Labs with co-principal investigators Dr. Eric Hyndman (PCC) and Dr. Adrian Fairey’s (NAUC).
Nanostics recognizes and is very grateful for the funding and support we received from the Bird Dogs from the beginning of this research and development journey. Nanostics also thanks funders for the clinical study including the Motorcycle Ride for Dad, Alberta Cancer Foundation, Alberta Innovates-ASBIRI program and the University Hospital Foundation Kaye Fund.

- Unknown